FUT4 and neoplasm: Among 102 assessable tumor specimens, 31 out of 44, (70 %), 8 out of 40 (20 %) and 1 out of 18 (6 %) of the CD15/FUT4-high, low and negative tumors were considered nonresponders to the therapy, respectively (P = 0.00000532; Table 1).